These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

709 related items for PubMed ID: 21632984

  • 1. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis.
    Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, Li J, Mattiazzi A, Ciancio G, Chen L, Zilleruelo G, Abitbol C, Chandar J, Seeherunvong W, Ricordi C, Ikehata M, Rastaldi MP, Reiser J, Burke GW.
    Sci Transl Med; 2011 Jun 01; 3(85):85ra46. PubMed ID: 21632984
    [Abstract] [Full Text] [Related]

  • 2. Rituximab's new therapeutic target: the podocyte actin cytoskeleton.
    Chan AC.
    Sci Transl Med; 2011 Jun 01; 3(85):85ps21. PubMed ID: 21632983
    [Abstract] [Full Text] [Related]

  • 3. Rituximab treatment prevents the early development of proteinuria following pig-to-baboon xeno-kidney transplantation.
    Tasaki M, Shimizu A, Hanekamp I, Torabi R, Villani V, Yamada K.
    J Am Soc Nephrol; 2014 Apr 01; 25(4):737-44. PubMed ID: 24459229
    [Abstract] [Full Text] [Related]

  • 4. Podocyte sphingomyelin phosphodiesterase acid-like 3b decreases among children with idiopathic nephrotic syndrome.
    Watanabe S, Hirono K, Aizawa T, Tsugawa K, Joh K, Imaizumi T, Tanaka H.
    Clin Exp Nephrol; 2021 Jan 01; 25(1):44-51. PubMed ID: 32946006
    [Abstract] [Full Text] [Related]

  • 5. Rituximab protects podocytes and exerts anti-proteinuric effects in rat adriamycin-induced nephropathy independent of B-lymphocytes.
    Takahashi Y, Ikezumi Y, Saitoh A.
    Nephrology (Carlton); 2017 Jan 01; 22(1):49-57. PubMed ID: 26833819
    [Abstract] [Full Text] [Related]

  • 6. Urinary excretion of sphingomyelinase phosphodiesterase acid-like 3b in children with intractable nephrotic syndrome.
    Watanabe S, Tsugawa K, Tsuruga K, Imaizumi T, Tanaka H.
    Pediatr Int; 2017 Oct 01; 59(10):1112-1115. PubMed ID: 29081073
    [Abstract] [Full Text] [Related]

  • 7. Novel unbiased assay for circulating podocyte-toxic factors associated with recurrent focal segmental glomerulosclerosis.
    Kachurina N, Chung CF, Benderoff E, Babayeva S, Bitzan M, Goodyer P, Kitzler T, Matar D, Cybulsky AV, Alachkar N, Torban E.
    Am J Physiol Renal Physiol; 2016 May 15; 310(10):F1148-56. PubMed ID: 26719363
    [Abstract] [Full Text] [Related]

  • 8. Fatal late-onset Pneumocystis pneumonia after rituximab: administration for posttransplantation recurrence of focal segmental glomerulosclerosis--case report.
    Dęborska-Materkowska D, Kozińska-Przybył O, Mikaszewska-Sokolewicz M, Durlik M.
    Transplant Proc; 2014 Oct 15; 46(8):2908-11. PubMed ID: 25380948
    [Abstract] [Full Text] [Related]

  • 9. The Importance of Sphingomyelin Phosphodiesterase Acid-Like 3b (SMPDL-3b) Levels in Kidney Biopsy Specimens of Children With Nephrotic Syndrome.
    Kaya M, Girişgen İ, Yalçın N, Becerir T, Şenol H, Gülten G, Yüksel S.
    Fetal Pediatr Pathol; 2023 Dec 15; 42(6):936-949. PubMed ID: 37818552
    [Abstract] [Full Text] [Related]

  • 10. Podocyte foot process effacement in postreperfusion allograft biopsies correlates with early recurrence of proteinuria in focal segmental glomerulosclerosis.
    Chang JW, Pardo V, Sageshima J, Chen L, Tsai HL, Reiser J, Wei C, Ciancio G, Burke GW, Fornoni A.
    Transplantation; 2012 Jun 27; 93(12):1238-44. PubMed ID: 22499148
    [Abstract] [Full Text] [Related]

  • 11. Sphingomyelinase-like phosphodiesterase 3b mediates radiation-induced damage of renal podocytes.
    Ahmad A, Mitrofanova A, Bielawski J, Yang Y, Marples B, Fornoni A, Zeidan YH.
    FASEB J; 2017 Feb 27; 31(2):771-780. PubMed ID: 27836988
    [Abstract] [Full Text] [Related]

  • 12. Identification of glomerular and podocyte-specific genes and pathways activated by sera of patients with focal segmental glomerulosclerosis.
    Otalora L, Chavez E, Watford D, Tueros L, Correa M, Nair V, Ruiz P, Wahl P, Eddy S, Martini S, Kretzler M, Burke GW, Fornoni A, Merscher S.
    PLoS One; 2019 Feb 27; 14(10):e0222948. PubMed ID: 31581251
    [Abstract] [Full Text] [Related]

  • 13. Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab.
    Alachkar N, Li J, Matar D, Vujjini V, Alasfar S, Tracy M, Reiser J, Wei C.
    BMC Nephrol; 2018 Dec 17; 19(1):361. PubMed ID: 30558559
    [Abstract] [Full Text] [Related]

  • 14. Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy.
    Alachkar N, Wei C, Arend LJ, Jackson AM, Racusen LC, Fornoni A, Burke G, Rabb H, Kakkad K, Reiser J, Estrella MM.
    Transplantation; 2013 Oct 15; 96(7):649-56. PubMed ID: 23842190
    [Abstract] [Full Text] [Related]

  • 15. Intrinsic tumor necrosis factor-α pathway is activated in a subset of patients with focal segmental glomerulosclerosis.
    Chung CF, Kitzler T, Kachurina N, Pessina K, Babayeva S, Bitzan M, Kaskel F, Colmegna I, Alachkar N, Goodyer P, Cybulsky AV, Torban E.
    PLoS One; 2019 Oct 15; 14(5):e0216426. PubMed ID: 31095586
    [Abstract] [Full Text] [Related]

  • 16. Protecting Podocytes: A Key Target for Therapy of Focal Segmental Glomerulosclerosis.
    Campbell KN, Tumlin JA.
    Am J Nephrol; 2018 Oct 15; 47 Suppl 1(Suppl 1):14-29. PubMed ID: 29852493
    [Abstract] [Full Text] [Related]

  • 17. Fibrinogen links podocyte injury with Toll-like receptor 4 and is associated with disease activity in FSGS patients.
    Wang H, Zheng C, Xu X, Zhao Y, Lu Y, Liu Z.
    Nephrology (Carlton); 2018 May 15; 23(5):418-429. PubMed ID: 28407405
    [Abstract] [Full Text] [Related]

  • 18. Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease.
    Yoo TH, Pedigo CE, Guzman J, Correa-Medina M, Wei C, Villarreal R, Mitrofanova A, Leclercq F, Faul C, Li J, Kretzler M, Nelson RG, Lehto M, Forsblom C, Groop PH, Reiser J, Burke GW, Fornoni A, Merscher S.
    J Am Soc Nephrol; 2015 Jan 15; 26(1):133-47. PubMed ID: 24925721
    [Abstract] [Full Text] [Related]

  • 19. Combination treatment with plasmapheresis and rituximab for recurrent focal segmental glomerulosclerosis after renal transplantation.
    Tsagalis G, Psimenou E, Nakopoulou L, Laggouranis A.
    Artif Organs; 2011 Apr 15; 35(4):420-5. PubMed ID: 20637013
    [Abstract] [Full Text] [Related]

  • 20. Rituximab in post-transplant pediatric recurrent focal segmental glomerulosclerosis.
    Kumar J, Shatat IF, Skversky AL, Woroniecki RP, Del Rio M, Perelstein EM, Johnson VL, Mahesh S.
    Pediatr Nephrol; 2013 Feb 15; 28(2):333-8. PubMed ID: 23052653
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.